ABIOMED, Inc. (NASDAQ:ABMD) Scheduled to Post Earnings on Thursday
ABIOMED, Inc. (NASDAQ:ABMD) will be posting its quarterly earnings results before the market opens on Thursday, July 27th. Analysts expect ABIOMED to post earnings of $0.42 per share for the quarter.
ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, May 4th. The medical equipment provider reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $124.68 million during the quarter, compared to analysts’ expectations of $122.82 million. ABIOMED had a net margin of 11.70% and a return on equity of 12.67%. The business’s revenue for the quarter was up 32.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 EPS. On average, analysts expect ABIOMED to post $1.84 EPS for the current fiscal year and $2.60 EPS for the next fiscal year.
Shares of ABIOMED, Inc. (NASDAQ ABMD) opened at 144.55 on Thursday. The firm’s 50 day moving average is $142.53 and its 200 day moving average is $126.78. ABIOMED, Inc. has a 12 month low of $95.14 and a 12 month high of $147.45. The company has a market cap of $6.30 billion, a PE ratio of 123.55 and a beta of 0.20.
ABMD has been the topic of a number of research analyst reports. Leerink Swann increased their price target on shares of ABIOMED from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, March 30th. Piper Jaffray Companies raised shares of ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 price target on the stock in a report on Thursday, April 6th. William Blair reissued an “outperform” rating on shares of ABIOMED in a report on Thursday, June 8th. BidaskClub lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 28th. Finally, Zacks Investment Research lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $151.86.
In other news, COO David M. Weber sold 21,250 shares of the firm’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $130.89, for a total value of $2,781,412.50. Following the completion of the sale, the chief operating officer now directly owns 123,771 shares of the company’s stock, valued at approximately $16,200,386.19. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Dorothy E. Puhy sold 13,500 shares of the firm’s stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $131.12, for a total transaction of $1,770,120.00. Following the completion of the sale, the director now directly owns 38,249 shares of the company’s stock, valued at $5,015,208.88. The disclosure for this sale can be found here. Insiders have sold a total of 53,629 shares of company stock valued at $7,072,580 in the last three months. 7.00% of the stock is currently owned by corporate insiders.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.